Hangzhou Shangjian Biotechnology Co., Ltd.

JAK inhibitors are a class of medications that work by blocking Janus kinases (JAKs), enzymes that are involved in the signaling pathways of various cytokines and growth factors. JAK inhibitors offer a more targeted approach to treating immune-mediated diseases compared to traditional therapies like corticosteroids or conventional immunosuppressants; this specificity reduces side effects and increases efficacy and is a major driver for the demand for JAK inhibitors. LAS VEGAS, Oct. 22, 2024 /PRNewswire/ -- DelveInsight's ' JAK Inhibitors Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline JAK inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the JAK inhibitors pipeline domain. Key Takeaways from the JAK Inhibitors Pipeline Report DelveInsight's JAK inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline JAK inhibitors. Key JAK inhibitors companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma, Esker Therapeutics, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical and others are evaluating new JAK Inhibitors drugs to improve the treatment landscape. Promising pipeline JAK inhibitors such as Povorcitinib, CPL409116, ATI-2138, SDC 1802, AZD 4604, INCB-160058, Research programme: JAK2 inhibitors, Ritlecitinib, Momelotinib, DZD4205, ATI 2138, CPL 409116, Itacitinib, Ivarmacitinib, ESK 001, Repotrectinib, Rovadicitinib, and others are under different phases of JAK inhibitors clinical trials. In October 2024, Pelabresib in combination with ruxolitinib showed benefit in treating patients with JAK Inhibitor-Naïve Myelofibrosis significantly reduced splenomegaly, and improved anemia that has not been previously treated with Janus kinase inhibitors (JAKis). In September 2024, Eli Lilly and Company and EVA Pharma announced that the companies have agreed to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. In May 2024, Ajax Therapeutics, Inc., announced that it had received clearance for its Investigational New Drug application from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study of AJ1–11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis. In February 2024, Novartis announced that it intends to acquire MorphoSys. The acquisition, which was unanimously approved by the boards of both Novartis and MorphoSys, is expected to close in the first half of 2024, subject to customary closing conditions. In January 2024, NS Pharma received orphan drug designation (ODD) from the European Commission (EC) for NS-229, which is being developed to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease. In December 2023, Sun Pharmaceuticals Inc. announced that it has entered a licensing agreement with Aclaris Therapeutics Inc., the company announced in a regulatory filing. Under the agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). Request a sample and discover the recent advances in JAK inhibitors drugs @ JAK Inhibitors Pipeline Report The JAK inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage JAK inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the JAK inhibitors clinical trial landscape. JAK Inhibitors Overview Janus kinase (JAK) inhibitors are a class of medications designed to interfere with the activity of the Janus kinase family of enzymes, which play a crucial role in the signaling pathways of immune responses. These enzymes are key mediators in transmitting signals from cytokines and growth factors, which regulate blood cell production and immune system function. By blocking these signals, JAK inhibitors help to control the overactive immune response seen in several inflammatory and autoimmune diseases. They have shown significant efficacy in treating conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, among others. The most common JAK inhibitors include tofacitinib, baricitinib, and upadacitinib, which are administered orally. Beyond their role in autoimmune diseases, JAK inhibitors are also being explored for use in treating certain cancers and myeloproliferative disorders, where abnormal JAK signaling contributes to uncontrolled cell growth. In diseases like myelofibrosis and polycythemia vera, JAK inhibitors can help reduce symptoms and improve quality of life. However, there are potential side effects associated with their use, including increased susceptibility to infections, blood clots, and cardiovascular risks, given their impact on the immune system. As research continues, the therapeutic potential of JAK inhibitors is expanding, offering new hope for patients with difficult-to-treat conditions. Find out more about JAK inhibitors drugs @ JAK Inhibitors Analysis A snapshot of the Pipeline JAK Inhibitors Drugs mentioned in the report: Learn more about the emerging JAK inhibitors @ JAK Inhibitors Clinical Trials JAK Inhibitors Therapeutics Assessment The JAK inhibitors pipeline report proffers an integral view of the emerging JAK inhibitors segmented by stage, product type, molecule type, and route of administration. Scope of the JAK Inhibitors Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Key JAK Inhibitors Companies: Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma, Esker Therapeutics, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical, and others. Key JAK Inhibitors Pipeline Therapies: Povorcitinib, CPL409116, ATI-2138, SDC 1802, AZD 4604, INCB-160058, Research programme: JAK2 inhibitors, Ritlecitinib, Momelotinib, DZD4205, ATI 2138, CPL 409116, Itacitinib, Ivarmacitinib, ESK 001, Repotrectinib, Rovadicitinib, and others. Dive deep into rich insights for new JAK inhibitors, visit @ JAK Inhibitors Drugs Table of Contents For further information on the JAK inhibitors pipeline therapeutics, reach out @ JAK Inhibitors Therapeutics Related Reports JAK Inhibitors Market JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Eli Lilly and Company, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Incyte Corporation, Kartos Therapeutics, Inc., Dompé Farmaceutici S.p.A, Sanofi, Kiniksa Pharmaceuticals, Ltd., Celgene, Abivax S.A., Telios Pharma, Inc., AstraZeneca, Karyopharm Therapeutics Inc, TWi Biotechnology, Inc., Geron Corporation, Ajax Therapeutics, Inc., among others. JAK Inhibitors Competitive Landscape JAK Inhibitors Competitive Landscape – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others. KRAS Inhibitors Market KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio , among others. PD/L-1 Inhibitors Market PD/L-1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD/L-1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

KRAS stands out as the most commonly altered among the trio of RAS genes, with NRAS and HRAS following suit. The human KRAS gene resides on chromosome 12p12.1 and comprises six exons, primarily positioned in exon 1 at sites 12 and 13, though occasionally found in codons 61, 63, 117, 119, and 146. The emergence of KRAS inhibitors marks a notable advancement in the rapidly progressing field of oncology, instilling hope in combating formidable solid tumors. The landscape of treatment for KRAS-mutant cancers is undergoing rapid evolution, marked by several promising advancements in recent years. Forecasts anticipate significant growth in the KRAS inhibitors market in the coming years, propelled by rising cancer incidence rates and the escalating demand for personalized cancer therapies. Ongoing research and clinical trials continue to unveil potential treatment strategies, fostering optimism for improved patient outcomes. According to DelveInsight’s analysis, the market size for KRAS inhibitors across the 7MM and is expected to grow with a tremendous 36% CAGR to reach USD 10 billion by 2032. As per the estimates, the US is set to be the largest market for KRAS inhibitors, with ~70% of the market share among the seven major markets. The KRAS inhibitor market is expected to grow significantly in the coming years, driven by the increasing incidence of cancer and the growing demand for personalized cancer treatments; ongoing research and clinical trials have identified potential treatment strategies. Key players, including Mirati, Novartis Pharmaceuticals, Amgen, Eli Lilly, Verastem, and others, are involved in developing drugs for KRAS mutation for various indications such as NSCLC, colorectal cancer, pancreatic cancer, and others. The treatment landscape for KRAS-mutant cancers has rapidly evolved, with several promising advancements in recent years. Keen to know how the KRAS inhibitors market will evolve by 2032? Find out @ KRAS Inhibitors Market Forecast Amgen and Mirati Therapeutics are at the forefront of the race to develop KRAS inhibitors for cancer treatment. However, their current candidates are focused solely on targeting G12C-mutant tumors, leaving a significant gap in addressing other KRAS variants. This represents a major unmet need in the field, as no approved treatments are currently available for other variants. Recognizing this challenge, numerous key players actively explore alternative KRAS variants and expand their research to include other types of cancers beyond NSCLC. This shift in focus holds promising potential for developing effective therapies that can address a wider range of KRAS mutations and target multiple cancer types. Many companies are focusing on developing their candidates in pan-KRAS, like Cardiff Oncology (onvansertib), Gritstone bio (SLATE KRAS), Hookipa Pharma (HB-700), and others. Now, let’s examine the emerging KRAS inhibitor therapies JDQ443: Novartis Pharmaceuticals Phase III JDQ443 represents an experimental KRASG12C inhibitor that is selective, covalent, and can be taken orally. Initial findings from the Phase Ib stage of the KontRASt-01 trial (NCT04699188) indicate a confirmed overall response rate (ORR) of 57% at the recommended dosage of 200 mg twice daily in individuals with advanced non-small cell lung cancer (NSCLC). Presently, JDQ443 is undergoing Phase III evaluation, aiming to compare its effectiveness as a standalone treatment against docetaxel in patients with advanced NSCLC carrying a KRASG12C mutation who have previously undergone platinum-based chemotherapy and immune checkpoint inhibitor therapy, either sequentially or in combination. Novartis intends to New Drug Application (NDA) for NSCLC by 2024 and for colorectal cancer (CRC) post-2026. Avutometinib (VS-6766): Verastem Oncology Phase II Avutometinib (VS-6766) functions as an RAF/MEK clamp, prompting the formation of inactive complexes involving MEK and ARAF, BRAF, and CRAF. This mechanism potentially enhances the anti-tumor response by thoroughly inhibiting the RAS pathway, possibly leading to more sustained effects. Currently, avutometinib is in advanced stages of development. Unlike other MEK inhibitors, it not only blocks MEK kinase activity but also prevents RAF from phosphorylating MEK. This distinctive mode of action enables avutometinib to inhibit MEK signaling effectively without triggering compensatory activation, a limitation observed in other inhibitors. The FDA has recognized the potential of avutometinib in combination with defactinib (a FAK inhibitor) by granting it Breakthrough Therapy designation for treating all patients with recurrent low-grade serous ovarian cancer (LGSOC), irrespective of their KRAS status, after one or more prior lines of therapy, including platinum-based chemotherapy. RAMP 201 is a trial aimed at registering avutometinib, either alone or combined with defactinib, in patients with recurrent LGSOC. RMC-4630 (SAR442720): Revolution Medicines Phase II RMC-4630 (also known as SAR442720) is a highly effective small compound intended for oral use, engineered to specifically hinder the function of SHP2. This essential cellular protein regulates cell survival and proliferation by transmitting signals from receptor tyrosine kinases to RAS. Currently, the company is in the Phase II trial stage, investigating the combination of RMC-4630 with sotorasib for individuals with non-small cell lung cancer harboring a KRAS G12C mutation. These patients have not responded to standard therapies and have not previously undergone treatment with an RAS inhibitor. Discover which therapies are expected to grab major KRAS inhibitors market share @ KRAS Inhibitors Market Report BI 1701963: Boehringer Ingelheim Phase I BI 1701963 is a compound designed to inhibit the activity of KRAS across various oncogenic variants, particularly targeting major G12 and G13 oncoproteins. Its mechanism involves binding to SOS1, a crucial component in activating KRAS by facilitating the exchange of RAS-bound GDP for GTP. This selective inhibition of SOS1 presents a promising therapeutic approach, enabling KRAS suppression regardless of mutation type. Preclinical studies demonstrate the efficacy of this pan-KRAS inhibitor in impeding tumor growth across numerous tested G12 and G13 KRAS mutations, which are commonly observed in the protein. Additionally, the compound exhibits selectivity towards cancer cell lines bearing mutations in the KRAS gene. Currently undergoing Phase I trials, BI 1701963 is being assessed both as a standalone treatment and in combination with trametinib for patients with advanced or metastatic solid tumors carrying KRAS mutations. Boehringer Ingelheim has initiated a clinical collaboration with Amgen to explore the potential of BI 1701963 in combination with LUMAKRAS. Divarasib/GDC-6036: Roche Phase I Divarasib/GDC-6036, an orally administered small molecule, exhibited strong and specific inhibition of the KRAS G12C protein in preclinical trials. Engineered to target the switch II pocket of the KRASG12C protein, it interacts specifically with the cysteine at position 12, effectively locking it in an inactive GDP-bound state irreversibly. Results from a Phase Ib study presented at AACR 2023 showed that combining GDC-6036 with cetuximab effectively treated colorectal cancer (CRC), displaying notable clinical efficacy and tolerable safety levels. LY353798: Eli Lilly Phase I LY353798 is a specific covalent blocker of KRASG12C, exhibiting efficacy both alone and when paired with other anti-cancer treatments in preliminary studies. Its pharmacokinetic pro well, prompting its progression to clinical trials. In laboratory settings, LY3537982 has displayed the ability to target the KRAS G12C mutation, hindering mutant KRAS-driven signaling. Phase I clinical trials are underway, focusing on patients with non-small cell lung cancer, colorectal cancer, or other advanced solid tumors. For further information on the most promising KRAS inhibitors, reach out @ KRAS Inhibitors Treatment Pipeline Related Reports PD-1 and PD-L1 Inhibitors Competitive Landscape PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others. Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others. Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Conference Coverage Solutions: DelveInsight’s Conference Coverage Solutions delivers a comprehensive examination of conference outcomes from a range of prominent events, such as ASCO, ESMO, ASH, AACR, ATS, ERS, EULAR, ELCC, and IPF Summit 2023. This in-depth analysis equips businesses with the insights they need for effective competitive intelligence and forecasting market trends, aiding in the development of future strategies. Contact Us Shruti Thakur info@delveinsight.com +14699457679

Cytegrity technology will aid in cost-effective lentiviral vector production for gene and cell therapies. Credit: Akimov Igor / Shutterstock.com. Contract development and manufacturing organisation (CDMO) Genezen has announced plans to license CSL ’s Cytegrity stable lentivirus production system. The advanced inducible technology produces lentiviral vectors (LVVs), which are vital for gene and cell therapies. The Cytegrity technology enables scalable and cost-efficient production of LVVs at clinically efficient titers. It has shown promising safety and efficacy results and is validated through early clinical testing. LVVs are generally manufactured on a small scale leveraging plasmid-based transient transfection technology. See Also: SG-2501 by Hangzhou Sumgen Biotech for Primary Systemic Amyloidosis: Likelihood of Approval STI-6129 by Sorrento Therapeutics for Primary Systemic Amyloidosis: Likelihood of Approval The Cytegrity system represents a significant advancement and is one of the first to facilitate continuous manufacturing from a stably transfected adherent or suspension cell line. This innovation alleviates the requirement for expensive plasmid inputs, reduces the complexity of the process and enables large-scale batch manufacturing. It also offers the potential for multiple harvests and reduced batch-to-batch variability to cut down production expenditures for Genezen’s clients. Genezen’s licensing of the Cytegrity system marks a substantial investment in next-generation technology for LVV production. The strategic move will provide its clients with immediate access to pioneering technology for stable and scalable high-titer clinical lentivirus production. The company is ready to provide the Cytegrity technology to its customers at its good manufacturing practice (GMP) facility in Fishers, Indiana, US. Genezen president and CEO Steve Favaloro said: “We have significant, hands-on experience scaling up and producing LVV using this stable production system at our GMP vector facility in Fishers, Indiana. “Stable producer cell lines can be developed for clients in under four months, and this system will help alleviate the current global viral vector shortage by providing customers with a scalable, high-quality vector platform. “This licensing capability is a significant value-add for our current and future LVV customers, and furthers our collective mission to bring gene and cell therapies more efficiently to patients.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy